However, many studies suggest that the inhibition of the TAK1 signaling pathway could alleviate the progression of NAFLD (Wang et al., 2016, 2018, 2021; An et al., 2017; Yan et al., 2017; Ji et al., 2018; Zhao et al., 2018; Ye et al., 2019; Liu et al., 2020, 2021). This evidence concerns the gene MAP3K7 and metabolic dysfunction-associated steatotic liver disease.